Matějková E, Foltánková V, Burešová I
National Tissue Centre, Brno, Czech Republic.
Folia Biol (Praha). 2013;59(4):146-53.
Graft-versus-host disease is a severe complication of allogeneic stem cell transplantation. The major role is played by alloreactive donor T-cell clones leading to host tissue damage. Selective depletion is a strategy to eliminate host-reactive donor T cells from haematopoietic stem cell allografts to prevent graft-versus-host disease while conserving useful donor immune functions. We have used irradiated peripheral blood mononuclear cells from cancer patients and healthy donor cells as responder cells in primary mixed leukocyte reaction. To prepare graft-versus leukaemia/myeloma-specific T cells, alloreactive T cells in primary mixed leukocyte reaction were depleted with anti-CD25 immunotoxin. The remaining T cells had insignificant alloreactivity in secondary mixed leukocyte reaction. Then, allodepleted donor T cells were repeatedly stimulated using purified leukaemia/tumour cells from the same cancer patient. Leukaemia/tumour-reactive donor T cells were purified using cell sorter on the basis of CD4 and CD8 activation. Their specificity was tested in nonradioactive cytotoxicity test. We performed 22 reactions (15 samples with leukemic and 7 samples with multiple myeloma cells). Selective depletion of alloreactive donor T cells with anti-CD25 immunotoxin led to significant depletion (99.2-100 %, median 99.7%). The effect of donor T cells was well preserved, while the graft-versus-host reactivation of donor cells was negligible, even after repeated stimulation with patient's non-tumour cells. Thus, it is possible to selectively deplete donor alloreactive T cells with anti-CD25 immunotoxin. In the cases of leukaemia patients, a strong graft-versus-leukaemia reactivity was noticed in allodepleted donor T cells; in myeloma patients, graft-versus-myeloma reactivity was less significant.
移植物抗宿主病是同种异体干细胞移植的一种严重并发症。主要由同种异体反应性供体T细胞克隆导致宿主组织损伤。选择性去除是一种从造血干细胞同种异体移植物中消除宿主反应性供体T细胞的策略,以预防移植物抗宿主病,同时保留有用的供体免疫功能。我们使用癌症患者经辐照的外周血单个核细胞和健康供体细胞作为初次混合淋巴细胞反应中的反应细胞。为制备移植物抗白血病/骨髓瘤特异性T细胞,初次混合淋巴细胞反应中的同种异体反应性T细胞用抗CD25免疫毒素去除。剩余的T细胞在二次混合淋巴细胞反应中同种异体反应性不显著。然后,使用来自同一癌症患者的纯化白血病/肿瘤细胞反复刺激去除同种异体的供体T细胞。基于CD4和CD8激活,使用细胞分选仪纯化白血病/肿瘤反应性供体T细胞。在非放射性细胞毒性试验中测试它们的特异性。我们进行了22次反应(15个白血病样本和7个多发性骨髓瘤细胞样本)。用抗CD25免疫毒素选择性去除同种异体反应性供体T细胞导致显著去除(99.2 - 100%,中位数99.7%)。供体T细胞的效应得到很好保留,而即使在用患者非肿瘤细胞反复刺激后,供体细胞的移植物抗宿主再激活也可忽略不计。因此,用抗CD25免疫毒素选择性去除供体同种异体反应性T细胞是可能的。在白血病患者中,在去除同种异体的供体T细胞中观察到强烈的移植物抗白血病反应性;在骨髓瘤患者中,移植物抗骨髓瘤反应性不太显著。